Sulfur Hexafluoride

Summary

Sulfur Hexafluoride (CHEMBL1796998) is an approved small molecule (ATC V08DA05); indicated across 24 conditions including breast neoplasm and breast carcinoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08DA05
• Indications: 24 conditions
• Clinical trials: 44
• Chemistry: 146.06 Da · F6S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1796998
Name	Sulfur Hexafluoride
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	17358
ChEBI	CHEBI:30496
ATC	V08DA05
Molecular formula	F6S
Molecular weight	146.06
InChIKey	SFZCNBIFKDRMGX-UHFFFAOYSA-N

SMILES: FS(F)(F)(F)(F)F

IUPAC name: hexafluoro-lambda6-sulfane

ChEBI definition: A sulfur coordination entity consisting of six fluorine atoms attached to a central sulfur atom. It is the most potent greenhouse gas currently known, with a global warming potential of 23,900 times that of CO2 over a 100 year period (SF6 has an estimated lifetime in the atmosphere of between 800 and 3,000 years).

Pharmacological roles (ChEBI): greenhouse gas.

Also known as: BRI, Lumason, Sonovue, Sulfur hexafluoride, Sulfur hexafluoride lipid microsphere, phospholipid microspheres, Sulphur hexafluoride, SULFUR HEXAFLUORIDE

Patent coverage: 33,851 distinct patent families (68,885 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

24 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
breast neoplasm	3	MONDO:0021100	MONDO:0007254
breast carcinoma	3	MONDO:0004989	EFO:0000305
heart disorder	3	MONDO:0005267	EFO:0003777
brain hypoxia - ischemia	3	MONDO:0006685	EFO:1000846
brain ischemia	3	MONDO:0005299	MONDO:0005299
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
pulmonary hypertension	2	MONDO:0005149	MONDO:0005149
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
portal hypertension	2	MONDO:0005080	EFO:0000666
renal cell carcinoma	2	MONDO:0005086	EFO:0000681
appendicitis	2	MONDO:0005649	EFO:0007149
kidney cancer	2	MONDO:0002367	MONDO:0002367
pancreatic ductal adenocarcinoma	2	MONDO:0005184	MONDO:0005184
vesicoureteral reflux	1	MONDO:0006007	EFO:0007536
tetralogy of fallot	1	MONDO:0008542	HP:0001636
lymphedema	1	MONDO:0019297	MONDO:0019297
cirrhosis of liver	0	MONDO:0005155	EFO:0001422
stroke disorder	0	MONDO:0005098	EFO:0000712
developmental dysplasia of the hip	0	MONDO:0000158	EFO:1000648

5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 44.

Phase distribution

Phase	Trials
PHASE3	13
Not specified	10
PHASE2	6
PHASE1/PHASE2	5
EARLY_PHASE1	4
PHASE1	4
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03235180	PHASE4	TERMINATED	Ultrasound Evaluation of Crohn’s Disease
NCT04569799	PHASE4	COMPLETED	Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE
NCT05648812	PHASE3	RECRUITING	Neonatal Brain Ultrasound With CEUS and Elastography
NCT06400004	PHASE3	RECRUITING	Lumason® Infusion vs. Bolus Administrations
NCT06497959	PHASE3	RECRUITING	Study of Placental Vascularization Using Contrast Ultrasound
NCT00000140	PHASE3	COMPLETED	The Silicone Study
NCT02522481	PHASE3	COMPLETED	Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141
NCT02552238	PHASE3	COMPLETED	Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142
NCT03290053	PHASE3	TERMINATED	Contrast Enhanced Sonothrombolysis and Sonolysis in Stroke - a Swedish Study (CE-5S)
NCT03385200	PHASE3	UNKNOWN	KVUS at Neoadjuvant CTx of Breast Cancer
NCT03549507	PHASE3	TERMINATED	CEUS Evaluation of Bowel Perfusion in Necrotizing Enterocolitis
NCT03549520	PHASE3	COMPLETED	CEUS Evaluation of Hypoxic Ischemic Injury
NCT04006275	PHASE3	UNKNOWN	Comparing SonoVue With Sonazoid Using CEUS-LIRADS in HCC
NCT04640038	PHASE3	COMPLETED	Contrast Enhanced Ultrasound in COVID-19
NCT05694611	PHASE3	WITHDRAWN	Preterm Neonates Brain Ultrasound With CEUS and Elastography
NCT06329570	PHASE1/PHASE2	RECRUITING	Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NCT07145801	PHASE2	RECRUITING	Y-90 Treatment Response Using Transarterial Radioembolization
NCT00286559	PHASE1/PHASE2	WITHDRAWN	Assessing Myocardial Blood Flow and Blood Flow Reserve by Transoesophageal Echocardiography (TEE)
NCT01306292	PHASE2	COMPLETED	Safety of SonoVue on Pulmonary Hemodynamics
NCT01678495	PHASE2	COMPLETED	Sonothrombolysis Potentiated by Microbubbles for Acute Ischemic Stroke
NCT01815320	PHASE2	COMPLETED	CE-US in Renal Transplantation
NCT03147690	PHASE1/PHASE2	TERMINATED	Contrast-Enhanced Ultrasound in the Evaluation of Abdominal Injuries in Children
NCT03477019	PHASE1/PHASE2	COMPLETED	Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer
NCT03687502	PHASE2	COMPLETED	The Role of Contrast Enhanced Ultrasound in Appendicitis
NCT04146441	PHASE2	COMPLETED	Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma
NCT04718441	PHASE1/PHASE2	COMPLETED	Contrast Ultrasound for Pediatric Trauma - Comparative Evaluation (CAPTURE Study)
NCT06600880	PHASE1	NOT_YET_RECRUITING	Neuronavigation-guided FUS-induced BBB Opening in Alzheimer’s Disease Patients and Its Effects on Brain Amyloid and Tau
NCT03295656	PHASE1	WITHDRAWN	Contrast-Enhanced Ultrasound Diagnosis of Acute Appendicitis
NCT03653702	PHASE1	UNKNOWN	Radiation-Free Technique for Evaluating Renal Scarring (RAFTERS)
NCT05613946	PHASE1	COMPLETED	Contrast-Enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema
NCT03107520	EARLY_PHASE1	RECRUITING	Intraoperative Contrast-Enhanced Ultrasound Evaluation of Blood Flow at the Time of Surgical Hip Reduction for DDH
NCT03296852	EARLY_PHASE1	COMPLETED	Study: SONAS Ultrasound for Detecting Stroke SONAS Ultrasound for Detecting Stroke
NCT03954015	EARLY_PHASE1	COMPLETED	Comparison of Three Methods for Early Detection of Breast Cancer
NCT05957042	EARLY_PHASE1	WITHDRAWN	Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).
NCT07274787	Not specified	NOT_YET_RECRUITING	Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma
NCT07365709	Not specified	NOT_YET_RECRUITING	Liver Cirrhosis Complicated by Clinically Significant Portal Hypertension
NCT00677963	Not specified	COMPLETED	Contrast-enhanced Ultrasound (CE-US) and Magnetic Resonance Imaging (MRI): Evaluating Plaque Neovascularisation
NCT01481441	Not specified	TERMINATED	Quantification of Contrast Enhanced Ultrasound (CEUS) in the Detection of Prostate Cancer
NCT02177045	Not specified	UNKNOWN	Breast Lesions Characterization on Contrast Enhanced Ultrasound With Histopathological Correlation
NCT02185469	Not specified	UNKNOWN	Corneal Endothelial Cell Loss After Pneumatic Retinopexy for the Repair of Primary Rhegmatogenous Retinal Detachment

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).